Literature DB >> 8837258

Focal xanthogranulomatous pyelonephritis presenting as renal tumour in children. Case report with a review of the literature.

V T Marteinsson1, J Due, I Aagenaes.   

Abstract

Xanthogranulomatous pyelonephritis (XGP) is a specific form of chronic inflammatory kidney disease which may involve both sexes at any age. The disease presents either in the diffuse form or less commonly as a focal process which is almost impossible to differentiate from renal malignancy. XGP usually occurs in association with urinary tract obstruction, infection and/or renal stones. Symptoms are often vague and non-specific. The most common offending organisms are E. coli and Proteus mirabilis. In reviewing the literature we have found 197 cases in children during the last thirty years, and of these only 15 (7.6%) were of the focal form. A case of focal xanthogranulomatous pyelonephritis in a 6-year-old boy is reported which demonstrates the diagnostic difficulties encountered in this disease. We emphasize the importance of XGP in the differential diagnosis of renal tumours in children with recurrent or therapy-resistant urinary tract infection in spite of no evidence of renal stone, poorly or absent function in the kidney or urinary tract obstruction.

Entities:  

Mesh:

Year:  1996        PMID: 8837258     DOI: 10.3109/00365599609181306

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  3 in total

1.  Xanthogranulomatous pyelonephritis in children: diagnostic and therapeutic aspects.

Authors:  Felicitas Eckoldt; Thomas Riebel; Stefan Wolke
Journal:  J Med Ultrason (2001)       Date:  2009-03-14       Impact factor: 1.314

2.  Cystic renal mass in a patient with previous Wilm's tumour.

Authors:  P Dilks; E Helbren; A Sohaib
Journal:  Br J Radiol       Date:  2012-10       Impact factor: 3.039

3.  Xanthogranulomatous pyelonephritis in Korean children.

Authors:  Jong Kil Nam; Sung Woo Park; Sang Don Lee; Moon Kee Chung
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.